Welcome to our dedicated page for Renovorx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on Renovorx stock.
Renovorx Inc (RNXT) pioneers targeted therapeutic delivery systems designed to transform cancer treatment and vascular interventions through its proprietary Trans-Arterial Micro-Perfusion technology. This page serves as the definitive source for verified updates about the clinical-stage innovator’s progress in precision medicine.
Investors and medical professionals will find comprehensive coverage of FDA clearances, clinical trial milestones, and strategic partnerships. Track developments in RNXT’s pipeline including oncology-focused device innovations and evidence-based research validating its Renovocath™ delivery platform.
Key updates include regulatory submissions, peer-reviewed study results, manufacturing collaborations, and financial performance reports. All content is curated to support informed analysis of RNXT’s position in the competitive medical device sector while adhering to strict journalistic standards.
Bookmark this page for streamlined access to essential RNXT developments. Combine our real-time updates with Stock Titan’s financial tools to monitor this innovator in localized therapeutic delivery systems.
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical firm specializing in localized treatment of solid tumors, is set to participate in two investor conferences in October 2022. CEO Shaun Bagai will present at the ROTH Inaugural Healthcare Opportunities Conference on October 6 and the LD Micro Main Event XV from October 25-27. He will discuss the company's therapy platform and address the challenges of treating pancreatic tumors. RenovoRx's lead product, RenovoGem, is in a Phase 3 trial targeting unresectable locally advanced pancreatic cancer.
RenovoRx, Inc. (NASDAQ: RNXT) recently announced Dr. Ripal Gandhi's presentation on Trans-Arterial Micro-Perfusion Therapy for Pancreatic Cancer at the Symposium on Clinical Interventional Oncology held in Miami Beach, Florida, from September 23-25, 2022. The presentation discussed challenges with the standard chemotherapy for locally advanced pancreatic cancer and highlighted the potential of RenovoRx's RenovoTAMP therapy, which aims to enhance chemotherapy efficacy and reduce side effects. The ongoing TIGeR-PaC study is evaluating the company's product candidate, RenovoGem, for improved patient outcomes.
RenovoRx, a biopharmaceutical company specialized in treating challenging solid tumors, has appointed Angela Gill Nelms as Chief Operating Officer. Ms. Nelms brings extensive expertise in clinical trial management and innovation, previously serving as COO at Florence Healthcare. Under her leadership, RenovoRx aims to expedite its Phase 3 TIGeR-PaC clinical trial and launch a new trial for extrahepatic cholangiocarcinoma. This strategic move aims to enhance the company's operational capabilities and advance its mission to lead in oncology therapies.
RenovoRx, a biopharmaceutical company listed on Nasdaq under the symbol RNXT, will participate in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, in New York City. CEO Shaun Bagai is scheduled to present on September 12 at 7:00 a.m. ET, discussing the challenges in treating pancreatic tumors and the innovative RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP™) therapy. One-on-one meetings will also be held with investors.
RenovoRx’s lead product, RenovoGem™, is under Phase 3 study for locally advanced pancreatic cancer.
RenovoRx, Inc. (Nasdaq: RNXT) reported its financial results for Q2 2022, revealing cash and cash equivalents of $10.8 million. R&D expenses rose to $1.4 million from $0.5 million year-over-year, while G&A expenses increased to $1.2 million from $0.3 million. The company reported a net loss of $2.6 million, up from $1.3 million in the previous year. Key developments include an upcoming interim analysis of the Phase 3 TIGeR-PaC clinical trial for pancreatic cancer and a new Phase 2/3 trial protocol submission. RenovoRx is advancing its proprietary RenovoTAMP therapy platform.
RenovoRx, Inc. (Nasdaq: RNXT) has appointed James Ahlers as Chief Financial Officer (CFO) effective July 15, 2022, replacing Christopher J. Lehman. Ahlers brings over 25 years of experience in life sciences finance, having managed capital-raising efforts exceeding $2 billion. Additionally, Ronald B. Kocak joins as Vice President and Controller, previously serving as interim controller. The leadership change aims to support the company’s focus on expanding its clinical pipeline and enhancing operations.
RenovoRx has announced the launch of a new video series titled 'The RenovoRx Story,' focusing on its innovative RenovoTAMP™ therapy platform for treating difficult cancers. The series introduces the leadership team and provides insights into their Phase 3 TIGeR-PaC clinical trial for locally advanced pancreatic cancer. CEO Shaun Bagai emphasized the potential benefits of localized treatment over traditional systemic chemotherapy. The trial aims to improve survival rates and quality of life for patients. Additional video segments will be released soon.
RenovoRx, Inc. (NASDAQ: RNXT) will host a webinar on June 21 at 8:00 AM ET, discussing its RenovoTAMP™ therapy platform for pancreatic cancer treatment. Featured speakers include Dr. Michael Pishvaian from Johns Hopkins Kimmel Cancer Center and CEO Shaun R. Bagai. Dr. Pishvaian will explore existing treatment options and the innovative approach of the TIGeR-PaC trial that localizes chemotherapy delivery to tumors. The event will include a Q&A session, with a recording available on RenovoRx's website post-event. RenovoRx focuses on enhancing local tumor treatment with its proprietary technology.
RenovoRx, Inc. (Nasdaq: RNXT) will present at the Gateway to Translation Webinar Series hosted by the University of Cambridge's Academy of Therapeutic Sciences on June 8, 2022. Dr. Ramtin Agah, CMO and Co-Founder, will discuss the RenovoTAMP™ therapy platform designed for pancreatic cancer treatment. This innovative approach aims to improve patient survival and reduce chemotherapy side effects. A recording will be available on the RenovoRx website. The company's lead candidate, RenovoGem™, is in a Phase 3 trial for locally advanced pancreatic cancer.
RenovoRx (RNXT) announced it will present preclinical research on its Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy for cholangiocarcinoma at the GEST 2022 in New York City. The study showed that intra-arterial delivery significantly penetrated bile duct tissue compared to gallbladder delivery. RenovoRx plans to launch a Phase 2/3 study in cholangiocarcinoma in the latter half of 2022 and has received Orphan Drug Designation for this indication. The findings aim to offer a localized chemotherapy option, enhancing treatment efficacy and potentially improving survival rates.
FAQ
What is the current stock price of Renovorx (RNXT)?
What is the market cap of Renovorx (RNXT)?
